SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

Near­ing a Phase II for its non-vi­ral gene ther­a­py, a small Cana­di­an biotech plans to com­bine with a For­bion-led blank check com­pa­ny to land a seat on Nas­daq and get to an FDA ap­proval re­quest in the first half of 2025.

With the help of ad­di­tion­al back­ers like Omega Funds, Cowen Health­care In­vest­ments, BVF Part­ners and oth­ers, en­Gene will snag about $135 mil­lion in cap­i­tal from its pro­posed mar­riage with For­bion Eu­ro­pean Ac­qui­si­tion Corp. The SPAC, formed by the Dutch VC fund just as blank checks were go­ing out of vogue, went through a $110 mil­lion IPO in De­cem­ber 2021. It had about $111 mil­lion in its trust at the end of March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER